Analysis shows minimal budget impact of treatments for schizophrenia in the US, suggesting affordability for health care plans.
The safety and tolerability profile of X/T, coupled with its minimal PMPM budget impact of $0.0177 in year 1 up to $0.1006 in year 3, based on market uptake of 1%, 2%, and 3% in years 1, 2, and 3, respectively, supports the inclusion of X/T on the formularies of third-party US health care plans for adults with schizophrenia.
No takes yet. Share an insight, caveat, or question.
Bjerke et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: